Bond.az White LogoBond.az Black Logo

Generac Stock Upgrade: Data Center Outlook

Jefferies upgrades Generac stock to Buy, citing data center prospects. Target price raised to $302. Stock up 100% in a year.

Isabella Martinez
ByIsabella Martinez- Senior Editor
|
0

Bond.az - Jefferies upgraded Generac Holdings (NYSE:GNRC) to Buy from Hold, raising its price target to $302 from $239.

The stock surged 100% past year and 82% year-to-date, trading at $247.79 with a market cap of $14.6 billion.

Analyst Tanner James cited data center contract conversion opportunities. The firm sees positive risk-reward with two potential announcements this year. Eight analysts revised earnings upwards.

Baudouin engines are being incorporated into hyperscaler configurations, indicating market acceptance for a product only Generac can scale effectively.

The stock trades at a P/E of 77.43. Bond.az analysis suggests shares may be overvalued relative to Fair Value.

Generac manufactures backup power generation products and engine-powered tools.

Recently, Generac reported Q1 2026 EPS of $1.80, beating forecasts of $1.35. Revenue reached $1.06 billion.

More News
Today / 14:04
|
264

Keefe Bruyette Reiterates Progressive Stock Rating at Market Perform

Keefe, Bruyette & Woods reiterates Market Perform rating on Progressive stock with $208 price target.

0
Today / 14:03
|
304

Datadog stock Buy rating reaffirmed

DA Davidson reaffirms Datadog Buy rating with $250 target, citing AI positioning and long-term growth.

0
Today / 12:50
|
462

KeyBanc Reiterates Overweight on Walmart, $145 Target

KeyBanc reiterates Overweight on Walmart with $145 target. Walmart shows strong market share gains and digital momentum despite recent stock decline.

0
Today / 12:23
|
531

Cantor Fitzgerald Reiterates Workday Rating on AI Growth

Cantor Fitzgerald reaffirms Workday Overweight rating, highlighting AI growth. Stock at $121.85, target $160.

0
Today / 12:21
|
379

Cantor Reiterates Overweight on ORIC Stock

Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.

0
Today / 12:20
|
278

Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight

Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.

0
Today / 12:13
|
680

Stifel reiterates IBM Buy after $1bn Chips Act award

Stifel reiterates IBM Buy rating after $1bn Chips Act award for quantum computing. Stock up 15%.

0
Today / 12:12
|
688

Stifel Maintains Buy on Deckers Outdoor at $140

Stifel reiterates Buy rating on Deckers Outdoor with $140 target. Stock shows strong growth potential and attractive valuation.

0
Today / 12:11
|
286

Argus Upgrades CAVA Group Stock Rating

Argus upgraded CAVA Group to Buy with a $92 target, citing improved restaurant traffic. Stock returned 66% in six months.

0
Today / 12:03
|
516

BofA raises Zoom price target on strong margins

BofA Securities raised Zoom's price target to $105, citing strong margins and free cash flow after Q1 results beat expectations.

0
Today / 11:53
|
249

Workday price target cut by Needham

Needham cuts Workday price target to $180 from $300, maintaining Buy rating. Workday beats revenue and income estimates, raises operating guidance.

0
Today / 11:53
|
473

BioMarin Neutral Rating, $50 Target by HC Wainwright

H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.

0
...